间充质干细胞治疗特发性肺纤维化药理机制研究进展  

Research progress on pharmacological mechanism of mesenchymal stem cells in treatment of idiopathic pulmonary fibrosis

作　　者：高雪 慈小燕 张英驰[1,2] 闫凤英 GAO Xue;CI Xiaoyan;ZHANG Yingchi;YAN Fengying(Center of Tianjin Cell Technology Innovation,Research and Development of Cellular Drug Quality Control Method and Quality Control System,Tianjin 300301,China;Tianjin He Chuang Biotechnology Co.,Ltd.,Tianjin 300301,China;Tianjin Institute of Pharmaceutical Research Co.,Ltd.,State Key Laboratory of Drug Release Technology and Pharmacology,Tianjin 300301,China;Chinese Academy of Medical Sciences,New Technology Innovation Unit of Drug Metabolism,Beijing 100050,China)

机构地区：[1]天津市细胞技术创新中心,天津300301 [2]天津和创生物技术有限公司,天津300301 [3]天津药物研究院释药技术与药代国家重点实验室,天津300301 [4]中国医学科学院药物代谢新技术创新单元,北京100050

出　　处：《药物评价研究》2022年第8期1679-1683,共5页Drug Evaluation Research

基　　金：中央引导地方科技发展专项(21ZYJDSY00120)。

摘　　要：间充质干细胞(MSCs)具有多种分化能力,可以直接迁移到损伤组织中并分化为肺泡上皮细胞,还可以分泌并释放多种细胞因子和外泌体,调节炎症和免疫反应。特发性肺纤维化(IPF)是与年龄相关、发病机制尚不明确的慢性进行性肺部疾病,临床上使用的吡非尼酮和尼达尼布仅能缓解症状。MSCs在治疗IPF方面具有广阔的应用前景,就目前关于MSCs治疗特发性肺纤维化的药理机制以及该疗法所存在的局限性进行综述和探讨。Mesenchymal stem cells(MSCs)have a variety of differentiation abilities,which can migrate directly to injured tissues and differentiate into alveolar epithelial cells.In addition,MSCs can secrete and release a variety of cytokines and exosomes to regulate inflammation and immune responses.Idiopathic pulmonary fibrosis(IPF)is an age-related chronic progressive disease with an unclear pathogenesis.The probable pathogenesis of IPF is the recurrent injury of the genetically susceptible alveolar epithelium followed by an abnormal repair response of excessive collagen deposition.The clinical use of Pirfenidone and Nintedanib can only alleviate the disease status of IPF patients.MSCs has broad application prospects in the treatment of idiopathic pulmonary fibrosis.To discuss the pharmacological mechanism of MSCs in the treatment of idiopathic pulmonary fibrosis and the limitations of this therapy.

关 键 词：间充质干细胞(MSCs) 特发性肺纤维化(IPF) 细胞分化 旁分泌作用 免疫调节 

分 类 号：R965.2[医药卫生—药理学] R967[医药卫生—药学]